What is the mortality rate of untreated unstable angina?

Mortality of Untreated Unstable Angina

Untreated unstable angina carries a substantial short-term mortality risk of approximately 4-13% within the first 28 days, with persistent symptoms and ECG changes being the strongest predictors of adverse outcomes.

Historical Natural History Data

The mortality risk of truly untreated unstable angina must be understood from historical studies conducted before modern antiplatelet therapy and revascularization became standard:

Acute Phase Mortality (First 28 Days)

• In-hospital mortality ranges from 4-13% in conservatively managed patients 1, 2
• One study of 100 patients treated conservatively (without routine beta-blockers, calcium antagonists, or anticoagulants) showed 1 death (1%) and 9 nonfatal infarctions (9%) within 28 days, for a combined adverse event rate of 10% 1
• A larger retrospective study of 158 patients demonstrated an acute mortality rate of 4% (6 deaths), with 20 patients (13%) developing myocardial infarction during hospitalization 2

One-Year Mortality

• Long-term mortality averages approximately 5% per year in hospital survivors 2
• In one cohort, 8 deaths, 14 nonfatal infarctions, and 3 readmissions for unstable angina occurred during 1-year follow-up 1
• The cumulative burden of death and myocardial infarction approaches 15-20% at one year when combining acute and follow-up events 1, 2

Key Prognostic Factors

The following clinical features predict unfavorable outcomes in untreated unstable angina:

High-Risk Clinical Features

• Persistence of pain beyond the first 24 hours is the strongest predictor of myocardial infarction or death 1, 2
• Magnitude and extent of ECG ST-T changes independently predict adverse outcomes 1
• Age >60 years significantly increases long-term mortality (P<0.05) 2
• Cardiomegaly on chest radiograph (P<0.01) and pulmonary venous congestion (P<0.05) predict higher mortality 2
• Absence of previous history of myocardial ischemia paradoxically increases risk of in-hospital infarction or death 2

Modern Era Context

The diagnosis and outcomes of unstable angina have changed dramatically with high-sensitivity troponin assays:

Declining Incidence

• Unstable angina now represents only 7-11% of acute coronary syndrome presentations in the high-sensitivity troponin era, compared to much higher proportions historically 3, 4
• The proportion has declined markedly, with one study showing unstable angina in only 2.8-8.9% of patients, while NSTEMI comprises 13-15% 3
• This represents a diagnostic shift where many patients previously classified as unstable angina are now diagnosed as NSTEMI 4

Contemporary Mortality with Treatment

Even with modern treatment, mortality varies by troponin level:

• Patients with undetectable high-sensitivity troponin (<5 ng/L): 0% mortality at 12 months 5
• Patients with normal troponin (5-14 ng/L): 1.9% mortality at 12 months 5
• Patients with stable elevated troponin (15-51 ng/L): 6.9% mortality at 12 months 5
• 30-day mortality in treated unstable angina: 0.5-0.7%, substantially lower than NSTEMI (3.7-7.4%) 3
• 1-year mortality in treated unstable angina: 3.3-5.1%, similar to non-cardiac chest pain but lower than NSTEMI (10.4-22.9%) 3

Critical Clinical Implications

The Untreated Scenario

Without intervention, unstable angina progresses to myocardial infarction in approximately 10-13% of patients within the first month 1, 2. The combined endpoint of death or myocardial infarction approaches 15-20% at one year in conservatively managed patients 1, 2.

Risk Stratification Imperative

• Patients with persistent pain require urgent intervention, as this feature alone predicts the highest risk of progression to infarction or death 1, 2
• ECG changes indicating ischemia mandate aggressive management, as their presence correlates with adverse outcomes 1
• The absence of troponin elevation does not eliminate risk, particularly in patients with ongoing symptoms or significant ECG changes 5

Modern Treatment Impact

The dramatic reduction in mortality from historical rates (4-13% acute mortality) to contemporary rates (0.5-0.7% at 30 days) underscores the critical importance of early antiplatelet therapy, anticoagulation, and revascularization when indicated 3, 6, 7. The 2020 ESC guidelines emphasize that even patients with unstable angina benefit from risk stratification and appropriate invasive management when high-risk features are present 8.